Locally Advanced Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase II, Open-Label, Multi-Centre Study of Camrelizumab Plus Apatinib As Consolidation Therapy in Patients With Locally Advanced, Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based concurrent chemoradiation therapy (cCRT) or sequential chemoradiation therapy (sCRT). This study will be conducted in China mainland.
This trial will evaluate the efficacy and safety of camrelizumab plus apatinib in participants with unresectable stage III NSCLC who have not progressed following definitive, platinum-based cCRT or sCRT. The primary endpoint is progression free survival (PFS) in the intent-to-treat (ITT) population. The secondary endpoints are as follows: 1) Overall survival (OS); 2) 1, 2, 3-year OS rates; 3) PFS rates at 12-monthand 18-month; 4) Objective response rate (ORR), 5) Duration of response (DoR); 6) Time to death or distant metastasis (TTDM); 7) Adverse effects (AEs) and severe adverse effects (SAEs) ;8) Quality of life (QoL).Exploratory objective is to explore potential biomarkers associated with efficacy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00702975 -
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
|
Phase 2 | |
| Recruiting |
NCT05339568 -
Patient's Whole Process Follow-up Management(HOPE-1)
|
||
| Recruiting |
NCT06287320 -
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
|
||
| Completed |
NCT01537991 -
ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial
|
N/A | |
| Completed |
NCT04648033 -
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
|
Phase 1 | |
| Completed |
NCT01059552 -
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
| Not yet recruiting |
NCT04153734 -
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT03371550 -
A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
|
Phase 2 | |
| Terminated |
NCT00614484 -
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05620199 -
Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy
|
N/A | |
| Withdrawn |
NCT05481775 -
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
|
Phase 2 |